Repligen (NASDAQ:RGEN) Price Target Raised to $175.00

Repligen (NASDAQ:RGEN) had its target price increased by JPMorgan Chase & Co. from $165.00 to $175.00 in a report issued on Wednesday,Benzinga reports. The firm currently has an overweight rating on the biotechnology company’s stock.

A number of other analysts have also recently weighed in on the company. Weiss Ratings raised Repligen from a “sell (d)” rating to a “sell (d+)” rating in a research report on Tuesday, July 14th. Evercore restated an “outperform” rating and set a $160.00 price target on shares of Repligen in a research note on Monday, July 6th. Benchmark raised Repligen from a “hold” rating to a “buy” rating and set a $185.00 price target for the company in a report on Tuesday, July 7th. Royal Bank Of Canada initiated coverage on shares of Repligen in a research report on Thursday, May 14th. They issued an “outperform” rating and a $160.00 price objective on the stock. Finally, HSBC dropped their price objective on shares of Repligen from $170.00 to $150.00 and set a “buy” rating on the stock in a research note on Wednesday, June 3rd. Two equities research analysts have rated the stock with a Strong Buy rating, twelve have assigned a Buy rating, two have given a Hold rating and one has given a Sell rating to the stock. According to data from MarketBeat, the stock presently has a consensus rating of “Moderate Buy” and an average price target of $166.43.

Repligen Trading Down 1.8%

NASDAQ RGEN opened at $141.01 on Wednesday. The firm’s fifty day moving average is $134.66 and its two-hundred day moving average is $131.60. Repligen has a one year low of $100.99 and a one year high of $175.77. The company has a debt-to-equity ratio of 0.26, a quick ratio of 7.78 and a current ratio of 9.05. The firm has a market cap of $7.95 billion, a PE ratio of 193.16, a P/E/G ratio of 2.67 and a beta of 1.06.

Repligen (NASDAQ:RGEN) last announced its earnings results on Tuesday, July 28th. The biotechnology company reported $0.54 earnings per share for the quarter, topping the consensus estimate of $0.45 by $0.09. Repligen had a net margin of 5.29% and a return on equity of 5.30%. The business had revenue of $204.13 million during the quarter, compared to the consensus estimate of $201.59 million. During the same quarter in the prior year, the firm earned $0.26 earnings per share. The business’s quarterly revenue was up 11.9% compared to the same quarter last year. Repligen has set its FY 2026 guidance at 2.030-2.090 EPS. Analysts expect that Repligen will post 2.06 earnings per share for the current year.

Insider Transactions at Repligen

In other news, CFO Jason K. Garland sold 733 shares of the firm’s stock in a transaction that occurred on Thursday, June 25th. The stock was sold at an average price of $145.00, for a total value of $106,285.00. Following the completion of the sale, the chief financial officer directly owned 19,359 shares of the company’s stock, valued at $2,807,055. This trade represents a 3.65% decrease in their position. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is available through this hyperlink. Insiders own 0.60% of the company’s stock.

Institutional Inflows and Outflows

Institutional investors and hedge funds have recently bought and sold shares of the business. United Capital Financial Advisors LLC purchased a new position in Repligen in the third quarter worth $368,387,000. Opti Capital Management LP purchased a new stake in shares of Repligen during the 4th quarter worth $2,399,209,000. Maverick Capital Ltd. purchased a new stake in shares of Repligen during the 1st quarter worth $178,946,000. Wasatch Advisors LP acquired a new position in shares of Repligen during the 1st quarter worth $146,513,000. Finally, Massachusetts Financial Services Co. MA acquired a new position in shares of Repligen during the 4th quarter worth $199,176,000. Institutional investors and hedge funds own 97.64% of the company’s stock.

About Repligen

Repligen Corporation (NASDAQ:RGEN) is a life sciences company that develops and manufactures high-value consumable products for bioprocessing applications. Founded in 1981 and headquartered in Waltham, Massachusetts, the company specializes in technologies that support the development and production of biopharmaceuticals. Repligen’s offerings include chromatography resins, filtration membranes, single-use technologies and systems for downstream purification and upstream processing.

The company’s core product lines encompass Protein A affinity resins, designed for monoclonal antibody purification, and a portfolio of ion exchange, multimodal and hydrophobic interaction resins.